title: Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC).
authors.affiliation: Astellas Pharma a/s, Kastrup, Denmark.
authors.forename: O
authors.initials: O
authors.lastname: Ghatnekar
authors.affiliation: Astellas Pharma a/s, Kastrup, Denmark.
authors.forename: K
authors.initials: K
authors.lastname: Nørgaard
authors.affiliation: Quintiles Consulting, Barcelona, Spain.
authors.forename: K
authors.initials: K
authors.lastname: Skaltsa